NDC product
Azor
NDC 0713-0871 · Cosette Pharmaceuticals, Inc.
Key facts
| Product NDC | 0713-0871 |
|---|---|
| Proprietary name | Azor |
| Nonproprietary name | amlodipine besylate and olmesartan medoxomil |
| Substances | AMLODIPINE BESYLATE, OLMESARTAN MEDOXOMIL |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | Cosette Pharmaceuticals, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA022100 |
| Pharmacologic classes | Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Dihydropyridine Calcium Channel Blocker [EPC] and 1 more |
| Marketing start | Sep 1, 2022 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: